Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).

Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).

Breast cancer is the leading cause of cancer related deaths in women worldwide and is classified into subtypes based on the cancer's receptor status. Of these subtypes, those expressing the human epidermal growth factor receptor 2 (HER2) receptor were traditionally associated with poor prognosi...

Full description

Bibliographic Details
Main Authors: Damien Coté, Alex Eustace, Sinead Toomey, Mattia Cremona, Malgorzata Milewska, Simon Furney, Aoife Carr, Joanna Fay, Elaine Kay, Susan Kennedy, John Crown, Bryan Hennessy, Stephen Madden
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC6071997?pdf=render

Internet

http://europepmc.org/articles/PMC6071997?pdf=render

Similar Items